US 12,128,104 B2
Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor
Rhett M. Schiffman, Laguna Beach, CA (US); and Lukas Scheibler, Laguna Beach, CA (US)
Assigned to CELLA THERAPEUTICS, LLC, Miami, FL (US)
Filed by Cella Therapeutics, LLC, Miami, FL (US)
Filed on Dec. 17, 2020, as Appl. No. 17/125,776.
Application 17/125,776 is a continuation of application No. PCT/US2019/037791, filed on Jun. 18, 2019.
Claims priority of provisional application 62/687,173, filed on Jun. 19, 2018.
Claims priority of provisional application 62/725,972, filed on Aug. 31, 2018.
Claims priority of provisional application 62/747,575, filed on Oct. 18, 2018.
Claims priority of provisional application 62/787,873, filed on Jan. 3, 2019.
Prior Publication US 2021/0100907 A1, Apr. 8, 2021
Int. Cl. A61K 38/08 (2019.01); A61K 38/10 (2006.01); A61K 45/06 (2006.01); A61K 47/52 (2017.01); A61K 47/60 (2017.01)
CPC A61K 47/52 (2017.08) [A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08)] 17 Claims
 
1. A drug delivery system comprising: a first active pharmaceutical ingredient (API), a second active pharmaceutical ingredient (API), and a sustained delivery component, wherein the first API is a ciliary neurotrophic factor (CNTF), wherein the second API is a FAS/FASL inhibitor, and wherein the first API is covalently bonded to the second API via a linking group.